The future of drug development is human.
The FDA and NIH are prioritizing human-based testing.
We make it possible.
Leading Organ-Chip Innovation Since 2014
30+ organ models across 130+ publications
Accepted into FDA ISTAND program
Sole Organ-Chip cited in the FDA Roadmap to Reducing Animal Testing
regulatory news
The FDA and NIH are phasing out animal testing. Don’t get left behind.
The future of preclinical safety is clear: Within the next 3-5 years, the FDA and NIH expect animal studies to be the exception rather than the norm for preclinical safety/toxicity testing1,2.
Organ‑Chips are the human‑relevant alternative the agencies are actively encouraging today. Backed by a uniquely close collaboration with the FDA—including the first and only Organ‑Chip accepted into the ISTAND program for DILI evaluation3—Emulate is the partner positioned to help you meet tomorrow’s regulatory standards, accelerate development timelines, and bring safer therapies to patients faster.
announcing
Emulate Launches AVA™ Emulation System to Accelerate Drug Development with First-of-its-Kind High-Throughput Organ-Chip Platform
Built-in incubation, automated imaging, and AI-ready data generation deliver in vivo fidelity at scale.
Read our press release to learn how AVA’s transformative capabilities give researchers the practical means to pivot beyond animal testing and into truly human-relevant territory.
Blog
